Physician profile
Sudhir Sinha
NPI 1659417095
$1,260.61
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $115 · 2021: $258 · 2022: $48.17.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $431.12 | 2019-2022 | |
| Pfizer INC. | $199.98 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $175.36 | 2019 | |
| Amarin Pharma, INC. | $114.77 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $97.80 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $73.68 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $56.00 | 2019 | |
| Glaxosmithkline, LLC. | $45.79 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.58 | 2021-2022 | |
| Lilly USA, LLC | $16.69 | 2020 | |
| Noven Therapeutics, LLC | $13.84 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudhir Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.